Xenon Therapy for Neurodegeneration and Alzheimer’s Disease
Approximately 6 million Americans and more than 30 million people worldwide have either clinical AD or mild cognitive impairment due to AD.
As the population ages, the U.S. numbers are expected to grow to 7.7 million by 2030 and approximately 16 million by 2050. Despite advances in understanding of Alzheimer’s disease (AD) biology, there are no disease-modifying treatments or preventions. The cost to the U.S. government is more than $200 billion a year (AD is the nation’s third most expensive disease). The financial costs, of course, do not include the enormous personal tragedy of AD for patients and their families, for which no cost can be assigned. Despite decades of research, the development of disease-modifying therapies has been difficult to achieve. Treatment of AD will require therapy that targets multiple pathways, and a combination of drugs will ultimately be required to control the disease.
Our Approach
We restore microglial phenotype and function to alleviate neuroinflammation.
Emerging evidence shows that homeostatic dysregulation of the brain’s immune system, which is orchestrated by microglia, plays a significant role in the onset and progression of AD. We recently identified homeostatic microglia and neurodegenerative microglia, also called disease-associated microglia (DAM), that are regulated by the reciprocal suppression of transforming growth factor beta (TGFβ) and induction of apolipoprotein E (APOE) signaling in different neurodegenerative models including AD. We showed that these MGnD are cytotoxic in multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and AD. However, the major question is how to restore microglial phenotype and function to treat AD. Restoring functional M0microglia in the brain of AD patients is an unmet need.
Our Technology
Xenon gas inhalation modulates microglial phenotype.
General Biophysics discovered that xenon gas treatment via inhalation modulates microglial phenotype associated with reduction in Aβ plaque pathology and neuroinflammation. Xenon penetrates the blood-brain barrier; suppresses expression of MGnD molecules, including APOE; and restores microglial functions in neurodegenerative diseases. Importantly, xenon gas treatment directly modulates the MGnD phenotype. Thus, xenon gas inhalation can serve as a novel treatment for AD and has clinical applicability for other neurodegenerative diseases.
General Biophysics demonstrated that xenon inhalation treatment modulates microglia and reduces Aβ in animal AD models, and it established an optimal xenon dose. Xenon is a biologically active noble gas used as an anesthetic in some countries. Xenon treatment has been shown to have an excellent clinical safety profile. Xenon crosses the blood-brain barrier and can act on CNS microglia. In the cellular membranes, xenon influences N-methyl-D-aspartate (NMDA) signaling and oxidative phosphorylation in microglia.
Our Product
The company’s product is a device-drug combination of xenon gas mixture and inhalation system.
It is a safe treatment that modulates microglia and inhibits neuroinflammation in a known and controllable fashion. This treatment is an intervention perhaps ultimately being given in an outpatient facility or at home by caregivers, that will reduce the burden to the health care system and being embraced by multiple stakeholders, including patients, clinicians, and payers. The expected benefit is that MGnD modulation will lead to slowing disease progression and cognitive decline.
Neurodegenerative diseases such as Alzheimer’s disease represent one of the greatest challenges in modern healthcare. With millions of people affected in the United States and worldwide, and no effective disease-modifying treatments available, there is an urgent need for innovative therapeutic approaches.
General Biophysics is developing xenon therapy as a novel solution for neurodegeneration. This approach focuses on targeting neuroinflammation and restoring the function of microglia—the brain’s immune cells that play a central role in disease progression.
Emerging research shows that dysregulation of microglial activity contributes significantly to Alzheimer’s disease and other neurodegenerative conditions. In particular, disease-associated microglia (DAM) promote inflammation and neuronal damage. Restoring healthy microglial function is a key therapeutic target.
Xenon gas inhalation offers a unique mechanism of action. Xenon crosses the blood-brain barrier and directly interacts with cellular processes in the central nervous system. It modulates microglial phenotype, suppresses harmful signaling pathways such as APOE expression, and reduces neuroinflammation.
Preclinical studies conducted by General Biophysics demonstrate that xenon therapy can reduce amyloid-beta plaque accumulation and improve microglial function in Alzheimer’s disease models. These findings highlight xenon’s potential as a multi-target therapeutic strategy.
The company is developing a drug-device combination that delivers a controlled xenon gas mixture through an advanced inhalation system. This approach is designed to be safe, scalable, and suitable for outpatient or home-based treatment.
By addressing the underlying biological mechanisms of neurodegeneration, xenon therapy has the potential to slow disease progression, preserve cognitive function, and reduce the burden on patients, caregivers, and healthcare systems.
What is xenon therapy for Alzheimer’s disease?
Xenon therapy is an innovative approach that uses xenon gas inhalation to reduce neuroinflammation, modulate microglial activity, and potentially slow cognitive decline.
How does xenon affect neurodegeneration?
Xenon crosses the blood-brain barrier and influences cellular signaling, helping restore microglial function and reduce harmful inflammation in the brain.
Can xenon reduce Alzheimer’s symptoms?
Research suggests xenon may reduce amyloid plaque pathology and support neuronal protection, potentially slowing disease progression.
What makes xenon different from other treatments?
Unlike traditional therapies, xenon targets multiple pathways, including inflammation and immune regulation, without significant side effects.
Is xenon therapy safe?
Xenon has an established safety profile as an anesthetic and is being studied for broader therapeutic applications in neurodegenerative diseases.